POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)

Trial details

Who runs it

Ethicon, Inc.

Trial code

NCT05299606

Record updated

24 November 2025

Original description

This is a prospective, multicenter, single-arm study on transbronchial microwave ablation using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone. The primary endpoint is Technique Efficacy, assessed 30-days post-ablation via CT imaging.Read full original descriptionShow less

A Prospective Multicenter Study of Transbronchial Microwave Ablation Using Robotic-Assisted Bronchoscopy in Subjects With Oligometastatic Tumors in the Lung

This is a prospective, multicenter, single-arm study on transbronchial microwave ablation using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone. The primary endpoint is Technique Efficacy, assessed 30-days post-ablation via CT imaging.

Inclusion: Signed informed consent; Subjects greater or equal to 22 years old; Performance status 0-2 (Eastern Cooperative Oncology Group classification (ECOG); Willing to fulfill all follow-up visit requirements; Subjects with at least one oligometastatic lung tumor where the primary tumor is controlled (in the opinion of the investigator or treating oncologist); Oligometastatic lung tumor(s) planned to be ablated in the outer two-thirds of the lung and not closer than 1cm to the pleura.

Exclusion: Subjects with thoracic implantable devices, including pacemakers or other electronic implants; Prior pneumonectomy; Subjects medically unable to stop anticoagulants (e.g., rivaroxaban, apixaban, dabigatran, endoxaban) at least 3 days prior to the ablation procedure through 48-72 hours after the procedure; Subject has had any radiation (i.e., SBRT or EBRT) to the intended ablation zone; Lung ablation, surgical resection therapy, radiotherapy, or any other treating procedure within 30 days prior to the planned study ablation procedure or those who plan to receive a lung ablation, surgical resection, or radiation therapy on the ablated lung side before completing the primary endpoint assessment (30 days post-ablation); Systemic therapy (e.g., chemotherapy, targeted drug therapy, or immunotherapy) within 14 days prior to the planned study ablation procedure or those who plan to receive systemic therapy before completing the primary endpoint assessment (30 days post-ablation); Chronic, continuous ventilator support, which uses bi-level positive airway pressure (PAP) to improve lung function for severe conditions. (However, intermittent PAP, for non-pulmonary conditions, such as sleep apnea, is permitted); Severe bronchiectasis (with FEV1 <30%) or disease deemed to be too severe in the opinion of the investigator; Platelet count ≤ 50,000/mm3; Subjects medically unable to stop anti-platelet agents (e.g., aspirin, clopidogrel, prasugrel, ticagrelor) at least 5 days prior to the procedure through 48-72 hours after the procedure; Subjects medically unable to stop warfarin at least 3-5 days prior to the ablation procedure, or until INR < 1.5, through 48-72 hours after the procedure. On the day of the procedure, subjects with an INR > 1.5 cannot have the procedure completed that day but may be rescheduled or postponed; Pregnant or breastfeeding; Subjects with uncorrectable coagulopathy at time of screening; Expected survival less than 6 months in the opinion of the investigator and/or treating oncologist; Subjects with known or suspected brain metastases; Endobronchial tumors proximal to and including the segmental airways.

ClinicalTrials.gov NCT05299606